Equities Analysts Offer Predictions for Clene Q1 Earnings

Clene Inc. (NASDAQ:CLNN) – Equities researchers at Roth Capital issued their Q1 2025 EPS estimates for shares of Clene in a research report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff expects that the company will post earnings of ($0.86) per share for the quarter. The consensus estimate for Clene’s current full-year earnings is ($5.26) per share. Roth Capital also issued estimates for Clene’s Q2 2025 earnings at ($0.86) EPS, Q3 2025 earnings at ($0.85) EPS and Q4 2025 earnings at ($0.75) EPS.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group lowered their target price on Clene from $86.00 to $83.00 and set a “buy” rating for the company in a research note on Thursday. EF Hutton Acquisition Co. I raised shares of Clene to a “strong-buy” rating in a research report on Tuesday, September 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $31.00 target price on shares of Clene in a report on Thursday.

Clene Stock Down 3.4 %

NASDAQ:CLNN opened at $4.53 on Friday. The stock has a market cap of $31.06 million, a price-to-earnings ratio of -0.86 and a beta of 0.42. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 1.66. The stock has a 50-day moving average price of $5.43 and a two-hundred day moving average price of $6.01. Clene has a 1 year low of $3.82 and a 1 year high of $12.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Clene stock. Castleview Partners LLC purchased a new position in shares of Clene Inc. (NASDAQ:CLNN) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned 0.19% of Clene as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 23.28% of the company’s stock.

Insider Activity

In other news, insider Mark Mortenson bought 20,512 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $97,432.00. Following the completion of the acquisition, the insider now owns 28,949 shares in the company, valued at approximately $137,507.75. This represents a 243.12 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David J. Matlin purchased 92,307 shares of the company’s stock in a transaction on Monday, September 30th. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $438,458.25. Following the completion of the transaction, the director now directly owns 444,491 shares of the company’s stock, valued at approximately $2,111,332.25. This represents a 26.21 % increase in their position. The disclosure for this purchase can be found here. 25.10% of the stock is owned by corporate insiders.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.